Clinical trials: Pneumococcal Immunization
Infections, Streptococcal, Streptococcus Pneumoniae Vaccines
Assess the Immunogenicity of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine
Evaluate the immune response of GSK Biologicals' 10-valent pneumococcal conjugate vaccine one month after completion of a 3-dose primary vaccination course administered at 2, 3, 4 months of age
- Trial name
- NCT00307541
- Testing
- Pneumococcal (vaccine)
- Where
- 32 sites in Germany
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pneumococcal Disease Prevention
Racial Disparities in Pneumococcal Vaccination in Managed Care
The goal of the study was to determine effectiveness of a telephone reminder to increase pneumococcal vaccination in a managed care population.
- Trial name
- NCT00229762
- Testing
- phone call from nurses - informational only
- Where
- United States
- Volunteers
- 7,000 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention
Immunogenicity, Vaccine, Immunologic Memory
Immunological Memory Against Pneumococcus Induced by 3 Infant PCV 13 Vaccination Schedules
The purpose of this study is to evaluate the establishment of immunological memory between the 3 different infant vaccination schedules with the 13-valent pneumococcal conjugate vaccine (PCV13) currently in use.
- Trial name
- NCT03405805
- Testing
- 13-valent pneumococcal conjugate vaccine (PCV13)
- Where
- Greece
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Aghia Sophia Children's Hospital of Athens
Infections, Streptococcal
COMPAS (Clinical Otitis Media & Pneumonia Study): Pneumonia & Acute Otitis Media (AOM ) Efficacy Study of the Pneumococcal Conjugate Vaccine
This is a study in a large number of healthy children less than 3 years old to measure the efficacy of GlaxoSmithKline (GSK) Biologicals' 10-valent pneumococcal conjugate candidate vaccine (Synflorix vaccine, or GSK1024850A) to…
- Trial name
- NCT00466947
- Testing
- Pneumococcal conjugate vaccine GSK1024850A, Havrix, Engerix-B
- Where
- 22 sites in Argentina, Colombia and 1 more
- Volunteers
- 23,802 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pneumococcal Vaccines
13vPnC Multidose Vial Safety, Tolerability and Immunogenicity Study in Healthy Infants.
This study will compare the immune responses of the infants who have been given 13vPnC in the mutidose vial formulation to the immune reponses of the infants who have been given 13vPnC in the single-dose syringe formulation.
- Trial name
- NCT01964716
- Testing
- 13-valent pneumococcal conjugate vaccine
- Where
- 2 sites in The Gambia
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Pfizer
Vaccination
A Clinical Trial to Evaluate the Safety and Immunogenicity of PPV23 Vaccine Revaccinated in 60-70 Years Old
Objective: To evaluate the safety and immunogenicity of PPV23 vaccine revaccinated in 60-70 years old in Shanghai.
- Trial name
- NCT04700618
- Testing
- 23-valent pneumococcal polysaccharide vaccine
- Where
- China
- Volunteers
- 330 people, healthy volunteers welcome
- Sponsor
- China National Biotec Group Company Limited
Pneumococcal Infections
Immunogenicity and Safety Study of NBP606 in Healthy Infants
This study will assess the immunogenicity and safety of primary vaccination with NBP606 compared to the existing commercial vaccine, when given concomitantly with routine pediatric vaccinations.
- Trial name
- NCT02201030
- Testing
- NBP606, Prevnar13
- Where
- South Korea
- Volunteers
- 577 people, healthy volunteers welcome
- Sponsor
- SK Chemicals Co., Ltd.
Vaccines, Pneumococcal
Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants
The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate (13vPnC) vaccine compared to Prevenar (7vPnC), when given concomitantly with routine pediatric vaccines in…
- Trial name
- NCT00366678
- Testing
- 13-valent pneumococcal conjugate vaccine, 7-valent pneumococcal conjugate vaccine, Pentavac
- Where
- 45 sites in France
- Volunteers
- 613 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Middle Ear Effusion, Tympanic Membrane Perforation
PneuMum: Pneumococcal Vaccination of Australian Indigenous Mothers to See if it Protects Their Babies From Ear Disease
PneuMum is a randomised controlled trial that aims to find out if pneumococcal vaccination for Australian Indigenous mothers, in the last few months of pregnancy or at delivery, can prevent ear disease in infants.
- Conditions
- Middle Ear Effusion, Tympanic Membrane Perforation, Acute Otitis Media, Pneumococcal Infections
- Trial name
- NCT00310349
- Testing
- 23 valent pneumococcal polysaccharide vaccine
- Where
- Australia
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- University of Melbourne
RA, SLE
Vaccination in Inflammatory Rheumatic Disease (VACCIMIL). The Impact of Antirheumatic Treatment on Antibody Response
The overall objective of this project is to study the influence of modern anti-inflammatory treatments in established inflammatory rheumatic diseases (IRD) on immune response elicited by pneumococcal vaccination using 13-valent…
- Conditions
- RA, SLE, Vasculitis, Scleroderma
- Trial name
- Vaccimil (NCT02240888)
- Testing
- 0,5 mg Prevenar i.m., 0,5 mg seasonal influenza vaccine i.m.
- Where
- Sweden
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Region Skane
Pneumococcal Immunization
Study of a Pneumococcal Conjugate Vaccine in Adults Aged 50 to 84 Years.
Primary Objectives: Assessed the immune response of the 3 SP0202 formulations, Prevnar 13 and Pneumovax 23 30 days after the administration of the single dose vaccination Assessed the safety profile of the 3 SP0202 formulations…
- Trial name
- NCT04583618
- Testing
- Pneumococcal Conjugate Vaccine - formulation 1-SP0202-IIb, Pneumococcal Conjugate Vaccine - formulation 2-SP0202-VI, Pneumococcal Conjugate Vaccine - formulation 3-SP0202-VII
- Where
- 17 sites in United States
- Volunteers
- 750 people, healthy volunteers welcome
- Sponsor
- Sanofi
Infections, Streptococcal
Study to Evaluate the Safety and Immunogenicity of a 10-valent Pneumococcal Conjugate Vaccine in Preterm Infants
This study aims to evaluate the safety, reactogenicity and immunogenicity of GlaxoSmithKline (GSK) Biologicals´ 10-valent pneumococcal conjugate vaccine when co-administered with diphtheria, tetanus, acellular pertussis-hepatitis…
- Trial name
- NCT00390910
- Testing
- Pneumococcal conjugate vaccine GSK1024850A, Infanrix hexa
- Where
- 8 sites in Greece, Spain
- Volunteers
- 286 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pneumococcal Infections
A Study To Assess The Safety And Effectiveness Of Prevenar In Chinese Children Who Have Not Previously Received A Vaccine Against Pneumococcal Bacteria
A vaccine called Prevenar is already approved for use in China for vaccination of children younger than 6 years old against infections caused by Streptococcus pneumoniae.
- Trial name
- 6114A1-4000-CN (NCT01193582)
- Testing
- Prevenar
- Where
- 5 sites in China
- Volunteers
- 505 people, healthy volunteers welcome
- Sponsor
- Pfizer
Influenza
Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine
This study is to evaluate the safety, tolerability and immune response when 13-valent pneumococcal conjugate vaccine (13vPnC) and the trivalent inactivated flu vaccine (TIV) are given together to healthy adults aged 50-59 years…
- Trial name
- NCT00521586
- Testing
- 13 valent pneumococcal conjugate vaccine
- Where
- 41 sites in United States
- Volunteers
- 1,116 people, healthy volunteers welcome
- Sponsor
- Pfizer
Vaccines, Pneumococcal
Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants.
The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate (13vPnC) vaccine compared to 7-valent pneumococcal conjugate (Prevenar/Prevenar®, 7vPnC), when given…
- Trial name
- NCT00366340
- Testing
- 13-valent pneumococcal conjugate vaccine, 7-valent pneumococcal conjugate vaccine
- Where
- 51 sites in Germany
- Volunteers
- 604 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer